
Copyright (c) 1994 Scientific American Medicine.

Clin Invest 19:20, 1989

•

25. Mustajoki P, Timonen K, Gorchein A, et al: Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest 22:407, 1992

•

26. Gorchein A, Webber R: Delta-aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci 72:103, 1987

•

27. Toback AC, Sassa S, Poh-Fitzpatrick MB, et al: Hepatoerythropoietic porphyria: clinical, biochemical, and enzymatic studies in a three-generation family lineage. N Engl J Med 316:645, 1987

•

28. de Verneuil H, Grandchamp B, Beaumont C, et al: Uroporphyrinogen decarboxylase structural mutant (Gly[281]•Glu) in a case of porphyria. Science 234:732, 1986

•

29. Lim HW, Poh-Fitzpatrick MB, Gigli I: Activation of the complement system in patients with porphyrias after irradiation in vivo. J Clin Invest 74:1961, 1984

•

30. Gibertini P, Rocchi E, Cassanelli A, et al: Advances in the treatment of porphyria cutanea tarda: effectiveness of slow subcutaneous desferrioxamine infusion. Liver 4:280, 1984

•

31. Ross JB, Moss MA: Relief of the photosensitivity of erythropoietic protoporphyria by pyridoxine (pt 2). J Am Acad Dermatol 22:340, 1990

•

32. Gordeuk VR, Brittenham GM, Hawkins CW, et al: Iron therapy for hepatic dysfunction in erythropoietic protoporphyria. Ann Intern Med 105:27, 1986

•

33. Pimstone NR, Gandhi SN, Mukerji SK: Therapeutic efficacy of oral charcoal in congenital erythropoietic porphyria. N Engl J Med 316:390, 1987

•

Acknowledgments

•

Figure 1 Dana Burns Pizer.

•

Table 1 Adapted from "Biochemistry of Porphyria," by M. R. Moore, in International Journal of Biochemistry 25:1353, 1993. Used by permission.

•

Table 2 Adapted from "Therapy of the Acute Porphyrias," by M. R. Moore and K. E. L. McColl, in Clinical Biochemistry

DSW 476038.1745

STLCOPCB4043894